Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Jul 2021

Isla D, de Castro J, García-Campelo R, Majem M, Vicente D, Juan-Vidal O

Abstract excerpt

AIM: To stablish a consensus on the treatment strategy for advanced non-small-cell lung cancer (aNSCLC) with epidermal growth factor receptor mutation (EGFRm) in Spain. METHODS: After a systematic literature review, the scientific committee developed 33 statements in 4 fields: molecular diagnosis (10 items); histologic profile and patient clinical characteristics (7 items); first-line (1L) treatment in EGFRm...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 33210237
DOI: 10.1007/s12094-020-02518-0
PMCID: PMC8192379

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus.PMID 33210237Read ↗

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.Semantic proximity Read ↗

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.Semantic proximity Read ↗

Consensus on the diagnosis and treatment of unresectable stage III driver gene-positive non-small cell lung cancer.Semantic proximity Read ↗

[Non-small lung cancer, ECCO/ESMO congres 2017].Semantic proximity Read ↗

EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy.Semantic proximity Read ↗

Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?Semantic proximity Read ↗

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.Semantic proximity Read ↗

An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach.Semantic proximity Read ↗

Clinical Outcomes Beyond 1L EGFR-TKI Progression in mNSCLC: Final Results of the Real-World Study 'LUNGFUL'.Semantic proximity Read ↗

Non-small cell lung cancer: how do experts want to be treated?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.